Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 3
1999 2
2000 6
2001 2
2002 4
2003 8
2004 7
2005 7
2006 5
2007 7
2008 7
2009 7
2010 5
2011 5
2012 3
2013 7
2014 6
2015 3
2016 1
2017 1
2018 5
2019 7
2020 3
2021 3
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis.
Andrews CP, Mohar D, Salhi Y, Tantry SK. Andrews CP, et al. Ann Allergy Asthma Immunol. 2020 Feb;124(2):171-178.e2. doi: 10.1016/j.anai.2019.11.007. Epub 2019 Nov 15. Ann Allergy Asthma Immunol. 2020. PMID: 31734334 Free article. Clinical Trial.
BACKGROUND: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). ...METHODS: In this phase 2, double-blind, parallel-group study, patients (12 years of age) with SAR wer …
BACKGROUND: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and m …
Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis.
Ayyappanavar S, Sridhar S, Kumar K, Jayanthi CR, Gangasagara SB, Rathod BLS, Preethi B, Mittal P. Ayyappanavar S, et al. Indian J Ophthalmol. 2021 Feb;69(2):257-261. doi: 10.4103/ijo.IJO_2083_20. Indian J Ophthalmol. 2021. PMID: 33463568 Free PMC article. Clinical Trial.
PURPOSE: To compare the efficacy and safety of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2%, and Bepotastine besilate 1.5% ophthalmic solutions in the treatment of allergic conjunctivitis. ...Each group was assigned to be treated with one of the three treatment …
PURPOSE: To compare the efficacy and safety of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2%, and Bepotastine besilate 1.5 …
Pupil Diameter, Corneal Thickness, and Anterior Chamber Alterations Following Topical Olopatadine Hydrochloride 0.1%: A Single-Masked Randomized Controlled Clinical Study.
Çavdarli C, Topcu Yilmaz P. Çavdarli C, et al. J Ocul Pharmacol Ther. 2020 Sep;36(7):540-544. doi: 10.1089/jop.2020.0007. Epub 2020 Apr 3. J Ocul Pharmacol Ther. 2020. PMID: 32250190 Clinical Trial.
Purpose: Olopatadine hydrochloride 0.1% is one of the known primary topical treatments in ocular allergy. ...Conclusion: Olopatadine 0.1% does not lead to a significant change in corneal topography or anterior chamber parameters. ...
Purpose: Olopatadine hydrochloride 0.1% is one of the known primary topical treatments in ocular allergy. ...Conclusion: Ol …
Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis.
Gross GN, Berman G, Amar NJ, Caracta CF, Tantry SK. Gross GN, et al. Ann Allergy Asthma Immunol. 2019 Jun;122(6):630-638.e3. doi: 10.1016/j.anai.2019.03.017. Epub 2019 Mar 22. Ann Allergy Asthma Immunol. 2019. PMID: 30910440 Free article. Clinical Trial.
BACKGROUND: GSP301 nasal spray is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). ...METHODS: In this double-blind study, eligible patients (12 years of age) with SAR were randomized 1:1:1:1 to twice-dai …
BACKGROUND: GSP301 nasal spray is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate …
Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis.
Dudeja L, Janakiraman A, Dudeja I, Sane K, Babu M. Dudeja L, et al. Indian J Ophthalmol. 2019 Sep;67(9):1400-1404. doi: 10.4103/ijo.IJO_2112_18. Indian J Ophthalmol. 2019. PMID: 31436181 Free PMC article. Clinical Trial.
Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for milder form of disease. There is no study directly comparing olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) f …
Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroi …
Olopatadine-mometasone combination nasal spray: Evaluation of efficacy and safety in patients with seasonal allergic rhinitis.
Hampel FC, Pedinoff AJ, Jacobs RL, Caracta CF, Tantry SK. Hampel FC, et al. Allergy Asthma Proc. 2019 Jul 3;40(4):261-272. doi: 10.2500/aap.2019.40.4223. Epub 2019 May 3. Allergy Asthma Proc. 2019. PMID: 31053180 Clinical Trial.
Background: GSP301 is an investigational fixed-dose combination nasal spray that contains the antihistamine, olopatadine hydrochloride (HCl), and the corticosteroid, mometasone furoate. ...Methods: In this double-blind, randomized, parallel-group study, patients (12 …
Background: GSP301 is an investigational fixed-dose combination nasal spray that contains the antihistamine, olopatadine hydrochlo …
Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
Butrus S, Greiner JV, Discepola M, Finegold I. Butrus S, et al. Clin Ther. 2000 Dec;22(12):1462-72. doi: 10.1016/s0149-2918(00)83044-1. Clin Ther. 2000. PMID: 11192137 Clinical Trial.
One drop of olopatadine was more efficacious than 29 drops of nedocromil. Olopatadine-treated eyes were rated as being significantly more comfortable than nedocromil-treated eyes (0.73 vs 1.55; P = 0.034). Of the 14 subjects treated with olopatadine and nedoc …
One drop of olopatadine was more efficacious than 29 drops of nedocromil. Olopatadine-treated eyes were rated as being signifi …
Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis.
Segall N, Prenner B, Lumry W, Caracta CF, Tantry SK. Segall N, et al. Allergy Asthma Proc. 2019 Sep 1;40(5):301-310. doi: 10.2500/aap.2019.40.4233. Epub 2019 Jun 27. Allergy Asthma Proc. 2019. PMID: 31248471 Clinical Trial.
Background: Safety and efficacy of GSP301 nasal spray, an investigational fixed-dose combination of olopatadine hydrochloride and mometasone furoate, was established in three large, 2-week seasonal allergic rhinitis studies. ...Methods: In this randomized, double-bl …
Background: Safety and efficacy of GSP301 nasal spray, an investigational fixed-dose combination of olopatadine hydrochloride …
Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Berdy GJ, Stoppel JO, Epstein AB. Berdy GJ, et al. Clin Ther. 2002 Jun;24(6):918-29. doi: 10.1016/s0149-2918(02)80007-8. Clin Ther. 2002. PMID: 12117082 Clinical Trial.
BACKGROUND: Olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension are topical antiallergic agents indicated for treatment of the signs and symptoms of allergic conjunctivitis and seasonal allergic conjunctivitis (SAC …
BACKGROUND: Olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension are topica …
Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
Vogelson CT, Abelson MB, Pasquine T, Stephens DM, Gamache DA, Gross RD, Robertson SM, Yanni JM. Vogelson CT, et al. Allergy Asthma Proc. 2004 Jan-Feb;25(1):69-75. Allergy Asthma Proc. 2004. PMID: 15055565 Clinical Trial.
This concentration of olopatadine provided significantly more efficacy than Patanol (olopatadine 0.1%) 24 hours after administration while being as effective as Patanol (olopatadine 0.1%) 5 minutes after administration. ...These data suggest that topically ap …
This concentration of olopatadine provided significantly more efficacy than Patanol (olopatadine 0.1%) 24 hours after administ …
106 results